D. Expected Annual Contract Values
The following financial schedule covers the contract term for 2023/24
|
Core Services |
2023/24 includes 1.8% uplift |
|
North Yorkshire Health and Care Partnership (Scarborough and Ryedale) |
£1,031,437 |
|
North Yorkshire Health and Care Partnership (Hambleton, Richmondshire and Whitby) |
£193,889 |
|
York Health and Care Partnership* |
£158,325 |
|
Total Value |
£1,383,651 |
Other Services – Scarborough and Ryedale only
|
Service Area |
2023/24 includes 1.8% uplift |
|
2nd consultant on Call services |
£7,985 |
|
Pharmacy Support |
£27,366 |
|
Hospice Drug Provision |
£38,221 |
|
Total Other Services |
£73,572 |
BCF Funded Services*** - Scarborough and Ryedale Only
|
|
2023/24 includes 1.8% uplift |
|
Nurse led beds
|
£143,364 |
|
Lymphoedema Services
|
£34,974 |
|
Integrated Palliative and End of Life Care Service
|
£296,622 |
|
Total BCF Funded Services |
£474,960 |
|
Total Value |
£1,932,183 |
|
Submission of monthly data in the format detailed in Schedule 6A (Activity Report – EOL Contract Data Collection) to aid reconciliation of new service costs.
The total annual value will be paid in four Quarterly payments on receipt of a valid invoice. Invoices for the total amount covering all Health and Care Partnership contributions should be submitted each quarter in advance to NHS North Yorkshire Health and Care Partnership at the following address: |
|
||
|
|
|||
|
|
|||
|
Reference numbers for invoices: XXZIQMNY
NHS HUMBER & NORTH YORKSHIRE ICB QOQ PAYABLES M835 PO BOX 312, LEEDS, WEST YORKSHIRE LS11 1HP
Notes:- |
|
||
|
|
|
||
|
*NHS North Yorkshire Health Care Partnership will undertake an internal recharge to the other Health and Care Partnerships as required. This arrangement will be review at the end of the current contract term or through contract variation if there are any changes to the current inter Health and Care Partnerships mechanism before the current contract end date.
|
|
||
|
**The responsibility of payment for Hospice high cost drugs is with the Responsible ICB commissioner. The ICB have agreed an indicative budget for payment of Hospice drugs based on pro rata expenditure in 2020/21. This is following the transfer of drug provision and support from York Teaching Hospitals NHS Foundation to an Independent pharmacy service provider. While the Hospice maintain the SLA agreement with the new provider, the cost of drugs will be reimbursed on a pass though basis in line with the National guidance on high cost drugs. Actual drug spend will be monitored on a regular basis on an open book approach, with quarterly reconciliation. Adjusting invoices / credit note will be applied following agreed reconciliation against budget following review, validation and agreement of the supporting information.
|
|
||
|
|
|||